; More treatment options emerge
Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out
Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

More treatment options emerge

VIEWS: 6 PAGES: 2

According to Herbert Meltzer, MD, a professor of psychiatry and pharmacology at Vanderbilt University and a consultant to its developer, ACADIA Pharmaceuticals, Inc., pimavanserin is aselective 5 HT2a inverse agonist - an antagonistthat also blocks endogenous basal activity in the area of the serotonin Zareceptor. [...] while it does not directly affect dopamine receptors, it has powerful effects on dopamine, glutamate, and GABA release through blockade of the stimulatory effects of dopamine on the affinity to neurons that release these key neurotransmittcrs.

More Info
To top